MEDPLUS: Adjusted EBITDA margin was 4.4%; FY27 guidance is ₹380-400 crores

What happened

Q2 revenue was ₹20,371 million and adjusted operating EBITDA was ₹901 million, or 4.4%, excluding a one-time retention-provision reversal. FY27 EBITDA guidance is ₹380-400 crores, with 800 net store additions targeted and planned cost efficiencies.

Confirmed

Global impact / market context

The 4.4% profit per sale figure, after stripping out a one-time accounting change, shows how much cash the pharmacy chain keeps from each rupee of sales. The FY27 EBITDA target of ₹380-400 crores gives investors a yardstick, which means a goal to measure future profit against.

Analyst inference

MedPlus is a pharmacy retailer, so its results track store expansion and medicine sales. Targeting 800 net new stores means higher rent and staff costs before new outlets earn money. Planned cost savings are meant to offset that spending and protect profit per sale.

Analyst inference

What to watch

1. FY27 EBITDA guidance is ₹380-400 crores, and 800 net store additions are targeted, so watch whether reported profit tracks that goal and how fast new stores open. Confirmed
2. The article says cost efficiencies are planned, so watch whether the company details which costs it will cut and how much savings it expects from each measure. Proposed
3. Watch whether the 4.4% profit per sale holds after the retention-provision reversal ends, since that one-time item flattered the reported figure and may not repeat. Analyst inference

Evidence

• Original source link unavailable